The RANTES Chemokine: A New Target for Immunomodulatory Therapy?

James M. Pattison, Peter J. Nelson, Alan M. Krensky*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

14 Scopus citations


RANTES is a member of the C-C family of chemoattractant cytokines (chemokines). It is secreted by T lymphocytes late after activation, and by fibroblasts, epithelial cells and endothelial cells after stimulation with tumour necrosis factor-α, interleukin-1β and interferon-γ. RANTES is a potent chemoattractant for monocytes, memory T cells, basophils and eosinophils. It also triggers basophil degranulation and activates eosinophils. RANTES is highly expressed in acute cell-mediated transplant rejection, in chronic inflammatory diseases such as sarcoidosis and atherosclerosis, and by some malignancies. This novel cytokine may play a pivotal role in the recruitment of the mononuclear cell infiltrate present in these conditions, and represents a potential target for new therapeutic agents.

Original languageEnglish (US)
Pages (from-to)1-8
Number of pages8
JournalClinical Immunotherapeutics
Issue number1
StatePublished - Jul 1995

ASJC Scopus subject areas

  • Immunology and Allergy
  • Pharmacology (medical)


Dive into the research topics of 'The RANTES Chemokine: A New Target for Immunomodulatory Therapy?'. Together they form a unique fingerprint.

Cite this